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Abstract
Until 2010, Burkina Faso was an exception to the international trend of abolishing user fees for antiretroviral
treatment (ART). Patients were still expected to pay 1,500F CFA (2 Euros) per month for ART. Nevertheless, many
non-governmental organizations (NGOs) exempted patients from payment. The objective of this study was to
investigate how NGOs selected the beneficiaries of payment exemptions for government-provided ART and
rationed out complementary medical and psychosocial services.
For this qualitative study, we conducted 13 individual interviews and three focus group discussions (n = 13
persons) with program staff in nine NGOs (4,000 patients), two NGO coordinating structures and one national
program. These encounters were recorded and transcribed, and their content was thematically analyzed. The
results were presented to the NGOs for feedback.
Results indicate that there are no concrete guidelines for identifying patients warranting payment exemptions.
Formerly, ART was scarce in Burkina Faso and the primary criterion for treatment selection was clinical. Our results
suggest that this scarcity, mediated by an approach we call sociotherapeutic rationality (i.e. maximization of clinical
success), may have led to inequities in the provision of free ART. This approach may be detrimental to assuring
equity since the most impoverished lack resources to pay for services that maximize clinical success (e.g. viral load)
that would increase their chances of being selected for treatment. However, once selected into treatment,
attempts were made to ration-out complementary services more equitably.
This study demonstrates the risks entailed by medication scarcity, which presents NGOs and health professionals
with impossible choices that run counter to the philosophy of equity in access to treatment. Amid growing
concerns of an international funding retreat for ART, it is important to learn from the past in order to better
manage the potentially inequitable consequences of ART scarcity.
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Introduction
Like the direct payment of healthcare services in Africa
[1], financial access to antiretroviral treatment (ART)
has been the subject of numerous debates and consider-
able research [2,3]. A review of the impact of user fees
on HIV/AIDS service delivery demonstrated that abol-
ishing user fees improved equity, by extending access to
the poorest users, and clinical results, by facilitating
treatment uptake and adherence [2]. Additionally, other
studies focused on Africa, such as one conducted in
Ethiopia, showed that free ART accelerated a reduction
in HIV-related mortality [4]. Studies in Senegal have
shown that the absence of fees for ART encouraged
treatment adherence [5]. The results of these studies, as
well as WHO and UNAIDS recommendations, may
explain why the majority of African countries have
eliminated user fees for ART [6].
Until 2010, Burkina Faso was an exception to this
trend of abolishing fees for ART, despite evidence
demonstrating that treatment costs and the costs of
complementary services such as laboratory monitoring
are important barriers to care [7]. This was somewhat
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relatively reticent about all forms of payment exemption.
Since the generalization of user-fees in the 1990s, few
exemption measures have been put in place and those
concerning the most impoverished were never imple-
mented [8]. Only in the past 10 years have a handful of
services been made free of charge, such as prenatal con-
sultations and tuberculoses treatment. Thus, the norm
in Burkina Faso is that patients pay for care at the point
of service delivery. Even when the State occasionally
consents to strongly subsidize a program, such as arte-
misinin-based combination therapies (ACT) and delivery
care, it continues to resist completely removing user-
fees. This is the case despite the African Union calling
for free delivery care and under-five medical consulta-
tions [9].
Before 2010, patients were still expected to pay a fee of
1,500F CFA (2 Euros) per month for ART, even though
46% of the population lives on less than 8,400F CFA per
month (13 Euros) [10]. While the fee for ART decreased
over time (it was 5,000F CFA in 2005), national authori-
ties continued to insist on obtaining user fees from
patients on treatment [11,12]. The State and non-govern-
mental organizations (NGOs) did, however, recognize
that certain individuals could not pay for treatment and
allowed these individuals to receive exemptions.
The medical management of people living with HIV/
AIDS (PLWHA) is not limited to the provision of ART.
Free antiretrovirals (ARVs) do not translate into free
treatment for patients, as there are other financial bar-
riers related to treatment and care. Medications for
opportunistic infections, medical exams, mental health
care, as well as nutritional support, travel costs, and
accommodation services are all a part of the treatment
and care “package.” Likewise, they can all influence
treatment adherence and, consequently, treatment suc-
cess [13,14]. In Senegal, the direct costs associated with
the medical management of PLWHA (not including
ARVs) were estimated to be around 15,000F CFA (23
Euros) per month [3]. In Burkina Faso, a 2006 study
showed that patients paid a median of 7,000F CFA (11
Euros) per month for medical exams, medications for
opportunistic infections and transportation [15].
For historical reasons, in Burkina Faso most care for
PLWHA occurs within nationally-based NGOs [16,17].
The State procures ARVs via the Global Fund to Fight
AIDS, Tuberculosis and Malaria and distributes them to
public services centres or NGOs based on estimated
needs. A survey in 2008 showed that approximately 60%
of patients on ART in the country were managed by
NGOs [18]. For the most part, these NGOs are charities
run by PLWHA that offer a number of services besides
treatment to support their members. There are financial
costs to the patient for each of these complementary
services.
Despite the national authorities’ insistence on impos-
ing fees for ART in Burkina Faso, a recent study showed
that 80% of patients sampled did not pay for treatment
[12]. Yet, we do not know how patients were selected
for payment exemptions or how other services were
rationed out [12]. More importantly, this study was a
cross-sectional analysis of those already receiving treat-
ment and thus, did not consider those patients who
failed to initiate treatment. One study in Uganda docu-
mented that 21% of ART eligible patients were lost to
follow-up [19] and in another study in Kenya, 37% of
ART ineligible patients were lost to follow-up before
becoming ART eligible [20]. Why these patients are lost
to follow-up is not known [21], but financial and social
barriers have been suggested [19].
The objective of this study is to shed light upon how
NGOs selected the beneficiaries of payment exemptions
for ART and how they rationed out complementary ser-
vices. We wanted to know how the ART selection pro-
cess evolved over time, as ART became increasingly
accessible in Burkina Faso. Given that public health pro-
grams often neglect the needs of the most impoverished
and the most vulnerable [22], the issue of equity is cen-
tral to our analysis. That is, we wanted to know how
patients were targeted for payment exemptions and
whether this was fair.
Methods
This is a qualitative study, which is a research approach
that allows us to document targeting processes and to
obtain the actors’ perspectives on them [23]. In the con-
text of the phenomenon studied here, in which situa-
tions change rapidly–such as the international funding
retreat that currently has NGOs worried [24]–this
means presenting the actors’ experiences and reactions
to events from a retrospective perspective.
This study looked at NGOs in Burkina Faso that were
involved in supporting and managing PLWHA. We
chose to focus on NGOs because of their long history of
providing ART in Burkina Faso and because they are
more explicit in basing their services on social justice
than the public sector. We expected NGOs to be more
equitable in their selection of participants for ART giving
us an idea of what the best-case scenario was for (in)
equitable selection processes in HIV treatment. Given
the limited time and resources available, we selected a
sample of NGOs that were members of the two largest
national networks. Among these NGOs, we retained
those that: i) had a substantial program, i.e., one follow-
ing at least 100 PLWHA; ii) had staff who had been
involved in the program for more than five years; and iii)
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tember 2008). The resulting sample consisted of nine
NGOs, two NGO coordinating structures and one
national program (Table 1). No NGO refused to partici-
pate in the study.
T h em a j o r i t yo fN G O si nt h es t u d ys t a r t i n go f f e r i n g
services thanks to support provided by French NGOs.
Association 1 is different from the other associations
because of the amplitude and diversity of its financing.
At the time of data collection, all of the associations
b e n e f i t e df r o mn a t i o n a lf i n a n c i n gt h r o u g ht h ePro-
gramme d’appui au monde communautaire (PAMAC,
funded by UNPD). Associations 1, 3, 5, and 6 have
national activities as well as smaller more decentralized
ones. The other associations are all local in scope. With
the exception of association 9, all can be found in the 2
largest cities of Burkina Faso (Ouagadougou and Bobo-
Dioulasso).
In these 12 organizations, we conducted 13 individual
interviews with coordinators. We also organized three
discussion groups, attended by a total of 13 coordinators
from three of these NGOs. The selection of participants
for the interviews and for the focus-group discussions
was conducted based on the participants’ specific knowl-
edge of the study subject. We therefore selected associa-
tion directors, managers, doctors, and counsellors. Data
collection was conducted in French by the second author
(PS) based on an interview guide devised in collaboration
Table 1 Descriptions of NGOs selected for the study
Community organizations with ARV prescription and patient management centres*
ORGANIZATION CHARACTERISTIC FEATURES NUMBER OF
BENEFICIARIES
PLWHA IN
TREATMENT BEING
FOLLOWED
Association 1 One of the first to implement a large-scale ARV treatment program. Very influential at
the national level and member of several international networks.
2692 969
Association 2 One of the first associations of people living with HIV and claiming this status. Member
of several international networks.
1075 273
Association 3 Association consisting mostly of women living with HIV. One of the first and largest
associations of women. Very influential at the national level and in certain international
arenas.
1947 856
Association 4 Association of women living with HIV. Groups of beneficiaries of a program to fight AIDS.
Transformation of a self-support group into an association for treating patients.
605 284
Community organizations providing support services for patients on ARV**
ORGANIZATION CHARACTERISTIC FEATURES NUMBER OF
BENEFICIARIES
PLWHA IN
TREATMENT BEING
FOLLOWED
Association 5 Association of youth. A prevention-focused organization that has evolved into an
organization providing support services to patients.
1486 308
Association 6 A prevention-focused organization that has evolved into an organization providing
support services to patients. Operates in the areas of community development and
poverty alleviation.
816 406
Association 7 Relatively young (2004) association of people living with HIV that provides support
services to its members.
246 205
Association 8 Relatively young (2005) association of people living with HIV whose members were
militant for a long time in other associations. Influential at the national level and
member of several international networks.
550 550
Association 9 Self-help and solidarity association that carries out development activities and that has
incorporated the fight against AIDS into its activities for the past 10 years. Member of an
international network.
540 159
Coordinating structures
ORGANIZATION CHARACTERISTIC FEATURES ACTIVE FILE PLWHA IN
TREATMENT BEING
FOLLOWED
Coordination 1 Coordinating structure for five NGOs involved in the screening council. N/A N/A
Coordination 2 Coordinating structure for eight NGOs involved in ARV distribution. N/A N/A
ARV
distribution
program
One of the largest ART funding programs in Burkina Faso. N/A N/A
* These organizations have treatment centres that serve as medical centres authorized to prescribe ARVs
** These organizations manage patients on ART and receive their ARVs from a coordinating structure
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individuals working for an association not included in
this sample. The interviews covered the distribution of
ART, the selection of beneficiaries, the organization of
patients’ non-medical services, and problems related to
targeting beneficiaries of services provided by the NGOs.
Individual interviews lasted between one and one and a
half hours. All interviews were digitally recorded and
fully transcribed by research assistants in Burkina Faso.
The analysis was inductive, without an analytic frame, in
order to rest as close as possible to the data. We manu-
ally analyzed the content thematically [25]. One of the
a u t h o r so ft h i sa r t i c l e( P S )h a db e e nw o r k i n gs i n c e2 0 0 0
f o ran a t i o n a lH I V / A I D SN G O( t h i sN G Ow a sn o t
included in the sample and the author has no conflicts of
interest with the other NGOs). While we could not con-
duct participant observation, this “insider knowledge”
helped to assure a good contextualization of the data as
well as a critical perspective on the participants’ dis-
course. We presented the results to the NGOs in Febru-
a r yo f2 0 0 9a n da tt h e5 t hF r a n c o p h o n eC o n f e r e n c eo n
HIV/AIDS (Casablanca, Morocco) in March of 2010. The
final research report was sent to the participating NGOs.
Results
The rejection of user fees and ART beneficiary selection
From the outset, we should note that most of our respon-
dents felt that selecting people to be exempted from pay-
ment for services made no sense. For members of these
NGOs, this type of targeting was inconceivable. They
gave several reasons for their position.
First, even though ART is currently widely available in
Burkina Faso, people remembered the 1990s, when ARVs
were scarce and necessarily rationed. At that time,
“selecting the beneficiaries of these treatments was hell-
ish,” recalled one program coordinator, who had received
16 treatments thanks to Northern partners. Second, our
respondents sometimes invoked the “pay it forward”
principle, i.e., since the NGOs received ARVs at no cost,
they felt the PLWHA should not have to pay either.
Given that these NGOs had provided treatment for free
since the beginning, one coordinator said, they “could not
see how they could backtrack now“. Even though they
knew “some people can afford to pay for treatment“,t h i s
coordinator continued, it was the idea of payment itself
that was inconceivable. “[Clearly,] we do not agree with
this national policy,” another coordinator said. The final
reason mentioned was the simple fact of being an NGO
member and asking for ART was enough to qualify
someone as vulnerable and entitled to receive medica-
tions for free.
Outside of this general view, there were a few indivi-
duals who supported patients’ financial participation in
accessing ART. They adopted this counter-position
from the perspective of preventing scarcity. Some
believed that financial contributions from patients able
to pay the treatment fee would help buffer against the
threat of recurrent stock-outs.
Selection criteria in situations of scarcity
When treatments first became available, most NGOs had
only a few units of ARVs and rationing was obligatory
[14]. The first criterion for selecting beneficiaries was clini-
cal, related to the conditionalities of treatment manage-
ment. Thus, “if we had five treatments for patients, those
who had had their full clinical work-up [CD4, viral load]
were first in line,” one physician told us. In this case, peo-
ple’s ability to pay for this costly workup was a factor in
their being selected. However, he later explained that
some people who had not had the workup, but whose clin-
ical condition was obvious enough to justify treatment,
were also treated. Given the importance of adherence to
treatment, NGOs also applied criteria other than medical
indications alone. One NGO physician explained that hav-
ing a companion to support treatment adherence was an
important criterion. Thus, people who were socially iso-
lated were excluded until they could find a companion.
Likewise, he added, another factor considered in patient
selection was a history of good compliance with antibiotic
treatment (e.g. Cotrimoxazole, used to prevent opportu-
nistic infections before the arrival of ARVs).
The previous scarcity of ARVs created a situation in
which providers selected patients based who was most
likely to succeed on treatment. One program coordinator
told us, “it was difficult for us to decide to put someone on
a treatment that was very costly back then, with no assur-
ance that this person would follow the regimen as diligently
as was required.” Thus, as this coordinator explained, even
though the NGO sometimes gave ART to “the really
poor... this was wasted, because they didn’t take their medi-
cations as indicated,” particularly because the poor were
often isolated and without “companions“ to help them fol-
low the treatment. Finally, with respect to ART activism, a
coordinator told us, “in this NGO, seniority and militancy
were the criteria applied.” The coordinator explained that,
for the NGO to survive and continue to fight for its cause,
its most militant activists needed to stay alive; “without
ART, they were in danger of being lost,” so they were the
first beneficiaries.
Triage for complementary services
Besides the provision of ARVs, HIV/AIDS treatment
includes additional services that are both medical (treat-
ments for co-morbidities, laboratory tests, etc.) and social
(nutritional and financial support, assistance to orphans
and vulnerable children). None of these services are free,
and decisions must be made as to who will receive them.
In providing nutritional support, schooling for orphaned
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that their concern has always been to serve the most
impoverished first. One program coordinator told us,
“if someone is well-off socio-economically, he will receive
fewer benefits than someone who seems to be at a lower
level.” This selection was based on the regularity of
patients’ incomes, their type of work, or their “standing“
as assessed through home visits. Widows were also
among the categories directly targeted by NGOs. Aside
from these broad categories, none of the NGOs had any
more precise criteria or more discriminating indicators.
However, most of our respondents thought that self-
selection, one form of targeting [26], was widely prac-
tised. Our respondents believed that those using NGOs
were mostly people who were destitute, often victims of
discrimination; “someone who has three meals a day
wouldn’tc o m ea n ds t a n di nal o n gl i n e - u pf o raf e w
kilograms of flour.”
Beyond these statements, no one was able to supply us
with any evidence that these criteria actually resulted in
complementary services being accessed by the worst-off.
Ultimately, those who received such services had already
passed through the first filter (i.e., they had already been
selected to receive ART); hence, it is unlikely that they
were the worst-off.
Criteria are loosely defined and applied with uncertainty
The NGOs did not have any official process to define
their selection criteria. We found no documentation on
this subject and had to rely only on our respondents’
statements. Sometimes an NGO would turn to the ser-
vices of the Ministry for Social Action, who is responsible
for issuing indigence certificates. However, “they said
that, even on their end, they couldn’t keep up and were
unable to produce indigence certificates because it took
time and resources,” one program coordinator recalled.
However, sometimes the contrary situation arose, in
which an agent of the Ministryw o u l dr e f e rap a t i e n tt o
the NGO because the NGOs were better acquainted with
indigents in the community. In some hospitals, in the
absence of indigence certificates, which were supposed to
be the only acceptable official document, the medical
team would organize its own patient selection committee.
However, this was a burdensome responsibility, “doctors
were often left to their own conscience, and that’s precisely
why we said, if only we could declare everything to be free,
once and for all...“ Only one of the NGOs set up a selec-
tion committee, but “this presented an ethical dilemma
because we didn’t have a clear and distinct methodology.”
This lack of any official definition was reflected in a
rather arbitrary application of selection criteria by peo-
ple without training for such selection processes. NGO
staff were left on their own in applying the criteria to
t h ep e o p l et h e ye n c o u n t e r e d ,e i t h e ra tt h eN G Oo r
during home visits. Agents’ subjective assessments, as
well as their experience, came into play; “we’re in con-
tact with each other, we know who is who,” one coordi-
nator said. Others worried about targeting errors,
because “when a man is faced with resources, he can
change radically and tell you things that are not neces-
sarily true, just to benefit from those resources.”
Discussion
The consequences of ARV scarcity & sociotherapeutic
rationality
At the national level, at the time of this writing, there were
no apparent stock-outs of State-procured ARVs. Ministry
officials told us that there seemed to have been no stock-
outs since mid-2007. However, because the country was
among those, in 2008, who reported still experiencing sup-
ply problems [27], we cannot conclude that at present,
there are no problems in the distribution chain. On the
continent as a whole, there is concern that supply-chain
disruptions will increase as funders cap, reduce, or with-
draw funding from ART programs [24,28].
T h ep a s th i g hc o s to fA R Tc o u p l e dw i t hs p o r a d i c
stock-outs led to a situation of scarcity that the actors in
our study recalled all too well. Therefore, the results of
this study suggest that scarcity, mediated by sociothera-
peutic rationality, may have led to a situation of inequi-
ties in the provision of ART. We use the term
sociotherapeutic rationality to describe the decision-mak-
ing process that ART providers use in choosing benefici-
aries of treatment. This process weighs social facilitators
and risk factors (e.g. lack companion for adherence assis-
tance, poverty, etc.) with potential patient outcomes. The
goal of this rationality is to maximize clinical success and
minimize the chances that patients “waste” scarce treat-
ment and services.
The first explicit criterion in this sociotherapeutic
rationality was clinical success. Those deemed most likely
to succeed on treatment were able to obtain the neces-
sary laboratory workup (CD4 count, viral load) and had
often shown previous ability to adhere to medications
such as Cotrimoxazole. The most socially and economic-
ally marginal members of society were, and continue to
be, those least likely to overcome these barriers and con-
sequently, many are lost to follow-up prior to becoming
eligible for treatment [19,20]. There is little research
describing the socioeconomic characteristics of those lost
to follow-up prior to ART initiation. One study showed
that ART ineligible patients lost to follow-up had signifi-
cantly lower BMIs than those who started treatment, sug-
gesting poorer nutritional status [20]. We also know that
after starting ART, loss to follow-up is associated with
the inability to pay for transport to health centres, as well
as work and childcare responsibilities [29] and that those
returning very late for treatment (CD4 less than 100) are
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ried men [30]. Unlike patients already on ART, who
receive medications and feel physical improvements with
treatment, ART ineligible patients receive few such
incentives and often have to pay for monitoring services
[20]. Those unable or unwilling to do so, will be lost
before being selected into treatment. Some will return
with advanced AIDS while a substantial minority will die.
In South Africa and Zambia, community support has
been shown to improve ART success and program reten-
tion [31,32]. However, in Burkina Faso, this type of com-
munity support for PLWHA is limited and is largely a
role taken on by NGOs and rarely the public health sys-
tem. Here, NGOs help provide nutritional support, edu-
cation on hygiene, and adherence support.
Social criteria, such as having a companion to help with
treatment adherence, were also a part of the sociothera-
peutic rationality used to select beneficiaries of treatment.
Those without means, such as orphans and widows, were
either excluded or forced to delay treatment until a com-
panion could be found. This is a situation similarly
described by Vuarin [33] in the neighboring country of
Mali, where people with means had greater social net-
works and support.
Delayed initiation of ART is a well-known risk factor
for early mortality on treatment [34,35]. More recently,
high one-year mortality has been demonstrated in those
who were ART eligible but failed to initiate treatment
[19]. Socioeconomic barriers that cause delays in receiv-
ing treatment are, for many, equivalent to being excluded
because of the strong association between delay and
death.
NGOs and doctors employing this sociotherapeutic
rationality find themselves in a tragic dilemma that pre-
vents them from being able to care for the sick without
discrimination. Sociotherapeutic rationality is con-
structed to the detriment of equity (it is unfair), since
the most impoverished lack the resources to pay for ser-
vices, such as viral load (often conducted in Europe or
Côte d’Ivoire), that would increase their chances of
being selected for treatment.
The idea of sociotherapeutic rationality invokes related
work in West Africa on therapeutic citizenship [36].
Nguyen’s research showed that claims were made on
the global social order based on a therapeutic predica-
ment (e.g. being HIV positive). At the beginning of the
period of access to ART, in order to make the strongest
claim on that social order, it was necessary to triage
among the most charismatic individuals to demonstrate
publicly and internationally that adherence to treatment
in Africa was possible [14]. It was vital to prove clinical
success to increase the flow of ARVs and this was best
done by selecting individuals most likely to succeed on
treatment (those with the support to be adherent to
treatment and the finances to pay for clinical monitor-
ing). While treatment has become more accessible, the
vestiges of this history of scarcity remain.
Rationing-out of complementary treatment services
The provision of complementary services, such as nutri-
tional and financial support, is likewise geared towards
the patient’s ultimate success. These complementary ser-
vices are important elements of the sociotherapeutic
rationality that NGOs employ in selecting service benefi-
ciaries. For example, it is well known that food insecurity
compromises ART adherence and reduces the clinical
effectiveness of treatment [37]. Similarly, financial sup-
port to help patients pay for transportation to medical
appointments or laboratory testing is intended to
improve medical management and, thus, chances of
treatment success. None of these services are free of
charge to patients in Burkina Faso [15], and NGOs must
triage patients to determine who should benefit from
these services. The results of this study reveal that there
are no concrete guidelines for identifying beneficiaries, a
situation that could intensify inequities, such that some
patients would receive adequate care and others, care
that is substandard. It is important to note that there are
no comprehensive food or financial aid programs sup-
ported by the NGOs in this study, which may explain
why people selected into ART programs benefit dispro-
portionately from complementary services.
On the other hand, it should be noted that, once the
issue of ART eligibility had been resolved, NGOs tried to
restore relative equity in the selection of beneficiaries for
complementary services. Still, we can hypothesize that,
for as long as the criteria remain arbitrary, initial self-
selection into the programs will mean that the chief ben-
eficiaries of such services will be the least poor among
the worst-off, i.e., those who can afford the prerequisite
workup [26]. This still needs to be demonstrated.
Abolishing fees for ART: insufficient to ensuring equity
The NGOs and the government of Burkina Faso have
inherently divergent perspectives on patients’ financial
participation in ART. For mostly social justice reasons,
N G O si nt h ec o u n t r ya r ef u n d a mentally against fees for
treatment, a position supported by WHO and UNAIDS
[6]. At the same time, despite previous government policy,
some government-run public health facilities also provided
free ART [12]. There was thus a disconnect between poli-
tical discourse and the actual situation on the ground.
Indeed, the government’s official position is that it has
always been preferable that patients pay for treatment, as
was demonstrated in an official speech during the organi-
zation of a conference on ART toward the end of 2008
[38]. One reason invoked for payment and supported by a
few NGOs was concern for the sustainability of treatment
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donors and not the State. Further, the monthly treatment
fee requested by the State does not fully recover the cost
of treatment. One study in Senegal showed, for instance,
that the government had the financial means to treat
patients without requiring user fees [39].
Given increasing evidence that eliminating fees for ART
increases treatment adherence, rendering ART free in
Burkina Faso could, in fact, improve long-term sustainabil-
ity. This is because population-level improvements in
treatment adherence could slow the development of drug
resistance [40], an issue that is all the more salient given
primary resistance levels already documented to be as
high as 29% in certain West African settings like Mali [41]
and at 13% in Ouagadougou Burkina Faso [42]. Drug
resistance, of course, necessitates the use of more expen-
sive second- and third-line treatments, threatening the
long-term sustainability of national ART programs.
The counter-position taken by a minority of our partici-
pants in favour of user fees mirrored that of the State, in
that it reflected a concern about treatment scarcity. Speci-
fically, certain participants believed that user fees could
buffer against stock-outs. Stock-outs of ARVs were a rea-
lity in some health facilities in Burkina Faso in 2007 [43],
as elsewhere on the continent [6,27]. One the biggest chal-
lenges to scaling-up treatment access is the prerequisite
reinforcement of fragile and complex supply chains.
Stock-outs also reduce patient motivation to adhere to
treatment [13]. Once again, the underlying logic behind
this counter-position in favour of user fees is to maximize
treatment efficacy; but this time, instead of focusing on
those individuals most likely to succeed on treatment, the
focus is on reducing scarcity in the first place.
With the exception of some discussion around the pro-
vision of complementary services to widows, it was rare
for participants to consider equity explicitly in the selec-
tion of beneficiaries. This lack of concern for the least
well-off is not new; health policy decision-makers in
Burkina Faso have often focused on equality of access to
the detriment of equity [8]. The nearly ubiquitous focus
on maximizing treatment success may stem from the
initial battle to obtain ARVs in developing countries.
Advocates for treatment access in developing countries
had to “prove” that clinical outcomes in resource-poor
countries could be as good as in resource-rich countries
a n dt h a tN o r t h e r np a r t n e r sw o u l dn o tb e“wasting” money
by supplying treatment to these contexts [14].
Study limitations
This study was conducted just prior to the 2010 deci-
sion by the Burkina Faso government to eliminate user-
fees for ART. Thus, results from this study should be
understood from a retrospective perspective. It will be
interesting to follow how NGOs adapt to the new
situation. The results of this article should not be gener-
alized as applying to the entire historical situation of
ART access in Burkina Faso as we did not interview
participants from the public sector nor did we meet
with representatives of every NGO in the country.
Further, the number of participants we met in each
NGO was relatively limited. Finally, this study is based
uniquely on qualitative data and should be understood
to represent the discourse and interpretations of the
informants we interviewed.
Conclusion
The provision of ART in Burkina Faso has changed dra-
matically in the past two years. At the time of data col-
lection, there were still user-fees for ART. On
December 31, 2009, after years of struggle, the NGOs of
Burkina Faso and many health professionals and
researchers scored a major victory. The President of the
Republic announced that ART would be free in Burkina
Faso. While this calls for celebration, some caution is
also in order. In removing the financial barrier to access,
the problem of selecting patients who will receive treat-
ment is resolved, if they are not lost prior to becoming
ART eligible. However, this decision will only be equita-
ble to the extent that it is actually applied, that stock-
outs do not recur, and that resources are allocated to
ensure that complementary services (particularly labora-
tory monitoring and transportation) and social support
will be accessible to patients unable to pay. If these con-
ditions are not met, it is possible that inequitable alloca-
tion of treatment and complementary services will
reoccur.
Concerns about repeating previous injustices are not
without merit. There is growing concern of an interna-
tional funding retreat for ART. The worldwide financial
crisis, donor fatigue, and the fraudulent use of Global
Fund money has encouraged donors to cap, reduce, or
withdraw funds from HIV treatment programs [24,28].
The global funding retreat has led to concerns about
increased treatment stock-outs, inability to add new
patients to treatment programs, and the re-emergence
of ARV user-fees [28,44]. In light of this, it is all the
more important to learn from the past in order to better
manage the “unfair” consequences of ART scarcity.
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